The FDA has approved a new type of painkiller that doesn't come with the risks of addiction and overdose associated with opioids.

Merck is ending a Phase 3 trial of Winrevair early so all PAH patients in HYPERION can start active treatment with the drug ...

One way to ease the strain on health systems is to put more emhasis on prevention. Having just raised $150 million, ...

AstraZeneca is no longer pursuing plans for a 450 million pound ($558.32 million) vaccine manufacturing plant in Speke, Liverpool, a company spokesperson said on Friday.

A gene-editing therapy for sickle cell disease, with a price tag of £1.65m, is to be offered to patients on the NHS in England. About 50 people a year with the inherited blood disorder are likely to ...

People in England with sickle cell will be able to get the world’s first CRISPR-based medicine under an agreement between the ...

One London clinic has become the first in Europe to offer the drug privately for an 'eye-watering' annual sum, after the NHS ...

“This new combination approach is an important breakthrough for patients with KRAS G12C-mutated metastatic colorectal cancer, offering a new beneficial treatment option for patients living with this ...

"On their path to get treatment, they are forced to sleep on roads, footpaths and subways - just keeping a flame of hope burning amidst the cold ground, hunger, and inconveniences," Gandhi said.

"Colorectal cancer is the third leading cause of cancer-related deaths in the United States, and fewer than one in five people diagnosed with metastatic disease survive beyond five years after ...

Future data on overall survival will be beneficial for prescribing the treatment to patients after the approval. 1. FDA approves sotorasib with panitumumab for KRAS G12C-mutated colorectal cancer.

The FDA has approved the combination of sotorasib (Lumakras) and panitumumab (Vectibix) for the treatment of patients with previously treated KRAS G12C-mutated metastatic colorectal cancer (CRC). The ...